Source comparison
Tesamorelin + Ipamorelin Blend Results Timeline: Phase Comparison
| Timeline Phase | Primary Physiological Changes | Measurable Outcomes | User-Reported Subjective Effects | Clinical Markers | Bottom Line ||—|—|—|—|—|| Week 1–2 | Receptor binding, initial GH pulse elevation, hepatic IGF-1 synthesis begins | No body compositi
This comparison does not assign a generated winner or score.
- | Timeline Phase | Primary Physiological Changes | Measurable Outcomes | User-Reported Subjective Effects | Clinical Markers | Bottom Line ||—|—|—|—|—|| Week 1–2 | Receptor binding, initial GH pulse elevation, hepatic IGF-1 synthesis begins | No body composition changes; possible transient water retention (+0.5–1.5 kg) | Improved sleep quality, deeper REM cycles, initial appetite modulation (increased or decreased) | GH peaks 30–50% higher than baseline; IGF-1 +15–30 ng/mL | Mechanism activation with no visible results. The foundation phase || Week 4–8 | IGF-1 stabilization, hormone-sensitive lipase activation, initial VAT mobilization, mTOR pathway upregulation | Subjective waist circumference reduction; DEXA lean mass +0.5–1.2 kg; strength gains 5–8% | Reduced abdominal bloating, improved skin elasticity, accelerated hair/nail growth, enhanced recovery | IGF-1 +80–120 ng/mL above baseline; fasting insulin −5–10% | First measurable body composition shifts. Patience required || Week 10